Chimeric Antigen Receptor T-Cell Therapy - Living Drugs: Case Histories of Transformational Advances
Harvard Business School Accounting & Management Unit Working Paper No. 21-035
Harvard Business School General Management Unit Working Paper No. 21-035
Posted: 29 Jun 2021 Last revised: 28 Dec 2024
Date Written: May 31, 2024
Abstract
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the development of CAR-T therapy, and 4) the situation in 2019.
Note: Funding Statement: Funding for this research was provided in part by Harvard Business School.
Declaration of Interests: We have no competing interests to report.
Suggested Citation: Suggested Citation